Clinical trials: Fibroblast Activation Protein Inhibitor, open to volunteers
Pleural Mesothelioma, Pleural Diseases
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging.
- Conditions
- Pleural Mesothelioma, Pleural Diseases, Cancer, FAPI
- Trial name
- FAPI-PM (NCT06790082)
- Testing
- [68Ga]Ga-FAPI-46 PET/CT
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Aalborg University Hospital
Fibroblast Activation Protein Inhibitor, PET/CT
68Ga-FAPI PET/CT in Malignant Tumors
Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms.
- Conditions
- Fibroblast Activation Protein Inhibitor, PET/CT, Malignant Neoplasm
- Trial name
- NCT05034146
- Testing
- 68Ga-FAPI, PET/CT
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
PASC Post Acute Sequelae of COVID 19, Long COVID
From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19
Rationale: The diagnosis and pathogenesis of long COVID remains unknown. We have previously shown that [68Ga]FAPI Positron Emission Tomography-Computed Tomography (PET/CT) imaging shows potential for diagnosis and molecular…
- Conditions
- PASC Post Acute Sequelae of COVID 19, Long COVID, Long Covid-19, PASC
- Trial name
- LIBERATE (NCT06911476)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Medullary Thyroid Cancer, Prositron Emission Tomography
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid…
- Conditions
- Medullary Thyroid Cancer, Prositron Emission Tomography, Fibroblast Activation Protein Inhibitor, Surgery
- Trial name
- NCT06277180
- Testing
- Surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences